Welcome to our dedicated page for PTNTD SEC filings (Ticker: PTNTD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTNTD SEC filings page aggregates regulatory documents for Palatin Technologies, Inc. that are associated with this symbol and related trading symbols referenced in the company’s disclosures. Palatin Technologies, Inc. files with the U.S. Securities and Exchange Commission as a Delaware corporation, as noted in its Form S-1/A registration statement, which also identifies a primary Standard Industrial Classification code of 2834.
On this page, users can review current reports on Form 8-K in which the company describes material events such as notices from NYSE American regarding listing suitability, the suspension of trading on that exchange, subsequent trading on OTC markets under the symbol "PTNT," and the company’s efforts to regain compliance with continued listing standards. These 8-K filings also cover underwriting agreements with A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd., detailing public offerings of common stock, pre-funded warrants, Series J and Series K warrants, and underwriter warrants.
The Form S-1/A registration statement available through this page outlines the structure of a firm commitment public offering, including the number of shares of common stock and warrants being registered, the assumed combined public offering price range, and the terms of the Series J and Series K common stock purchase warrants and pre-funded warrants. It also discusses conditions related to the re-listing of the company’s common stock on the NYSE American exchange.
In addition, 8-K filings describe a collaboration agreement with Boehringer Ingelheim International GmbH, including upfront and milestone payments and the potential for additional success-based payments and royalties. Stock Titan’s interface can pair these filings with AI-powered summaries that explain the key terms of offerings, warrant structures, listing status changes, and collaboration arrangements, helping readers interpret lengthy documents such as 8-Ks and S-1/A filings more efficiently while they research PTNTD-related information.
Palatin Technologies reported a director equity grant for John K.A. Prendergast. On December 9, 2025, he received 2,600 restricted stock units under the 2011 Stock Incentive Plan, split into two grants of 1,300 units each. One grant vests fully on December 9, 2026, and the other vests 50% on December 9, 2026 and 50% on December 9, 2027, each unit representing one share of common stock at no purchase price.
He was also granted 3,200 stock options at an exercise price of $21.38 per share in two blocks of 1,600 options, both expiring on December 9, 2035. One option grant vests on December 9, 2026 with potential monthly proration if service ends before December 31, 2026, while the other vests 50% on December 9, 2026 and 50% on December 9, 2027. Following these transactions, he beneficially owned 15,102 shares of common stock and 27,281 stock options directly.
Palatin Technologies, Inc. reported equity awards to a director in the form of restricted stock units and stock options under its 2011 Stock Incentive Plan. On December 9, 2025, the director received two grants of 1,000 restricted stock units each, at a price of $0 per share, increasing common stock holdings to 14,081 shares held directly after these awards.
The first restricted stock unit grant vests in full on December 9, 2026. The second vests 50% on December 9, 2026 and 50% on December 9, 2027. On the same date, the director was also granted two stock option awards covering 1,200 shares each at an exercise price of $21.38 per share. One option grant vests on December 9, 2026 with proration if board service ends before December 31, 2026, and the other vests 50% on December 9, 2026 and 50% on December 9, 2027.
Janus Henderson Group plc has disclosed a significant ownership position in Palatin Technologies, Inc. common stock. The filing reports beneficial ownership of 170,097 shares, representing 9.99% of Palatin’s common stock, including certain pre-funded and common stock warrants that are exercisable within 60 days but subject to a 9.99% beneficial ownership cap.
The disclosure notes that, because of this cap, an additional 8,562 pre-funded warrants and 182,000 Series J and 182,000 Series K common warrants are not included in the reported figures. A related reporting person, Janus Henderson Biotech Innovation Master Fund Ltd, is shown as beneficially owning 118,196 shares, or 6.6% of the class, with shared voting and dispositive power. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Palatin.
Palatin Technologies executive Stephen T. Wills, Executive VP and CFO/COO, reported routine share-withholding transactions related to tax obligations. On November 14, 2025, the issuer withheld small amounts of common stock (33, 22, 79 and 95 shares) to cover employee withholding taxes tied to previously vested equity awards. The per-share values used were $8 for three grants and $5.5 for one grant, as determined on the respective vesting dates in June 2025. Following these transactions, Wills directly beneficially owned 32,583 shares of Palatin Technologies common stock. The filing is indicated as a Form 4 for one reporting person and reflects tax-related administrative activity rather than an open-market trade.
Palatin Technologies (PTNT): Logos Global Management and affiliated entities filed a Schedule 13G reporting beneficial ownership of 142,292 shares of Common Stock, representing 9.9% of the class. The reporting persons have 0 sole voting/dispositive power and 142,292 shared voting/dispositive power.
The filing lists Logos Global Management LP, Logos Global Management GP LLC, Logos Opportunities Fund IV LP and GP, Arsani William, and Graham Walmsley as reporting persons. The percentage is calculated based on 140,000 shares and warrants to acquire 224,000 shares, and 1,422,060 shares outstanding following the issuer’s offering on November 6, 2025. They certify the holdings are in the ordinary course and not to influence control.
Palatin Technologies Inc. received a Schedule 13G showing that Point72 entities and Steven A. Cohen reported beneficial ownership of 2,307,000 shares of Common Stock, representing 9.9% of the class as of November 12, 2025. The position includes 2,192,000 shares issuable upon exercise of warrants, with certain warrants subject to a 9.99% blocker that limits exercises that would push ownership above that threshold.
The reporting persons list shared voting and dispositive power over 2,307,000 shares and no sole voting or dispositive power. Point72 Asset Management, L.P. manages the securities held by Point72 Associates, with Point72 Capital Advisors, Inc. as its general partner, and Mr. Cohen controlling both entities. The certification states the securities were not acquired for the purpose of changing or influencing control, consistent with a passive Schedule 13G filing.
Palatin Technologies reported that underwriters exercised their over-allotment option tied to its recent public offering. The underwriters purchased 280,615 common shares at $6.50, plus pre-funded warrants for 84,000 shares at $6.50, and the company issued accompanying Series J warrants to buy up to 364,615 shares at $6.50 and Series K warrants to buy up to 364,615 shares at $8.125. This added approximately $2.37 million in gross proceeds, before fees and expenses.
After giving effect to the over-allotment exercise, total gross proceeds from the offering rose to approximately $18.2 million. Palatin also filed a legal opinion covering the securities and noted a related press release.
Palatin Technologies (PTNT) entered an underwriting agreement for a public offering of 2,430,769 shares of common stock (or pre-funded warrants in lieu) together with Series J and Series K warrants at a combined public offering price of $6.50 per share and accompanying warrants. The company expects gross proceeds of approximately $15.8 million, with a 45-day option for up to 364,615 additional shares. Closing is expected on or about November 12, 2025, subject to the resumption of trading on NYSE American.
Series J Warrants have a $6.50 exercise price and an expiry tied to the earlier of 18 months or 31 days after FDA acceptance of an IND for an in-house obesity treatment compound. Series K Warrants have an $8.125 exercise price and a five-year term, subject to early termination if Series J conditions aren’t met before the FDA exercise period ends. The company noted a prior 1-for-50 reverse split and submitted pro forma materials supporting compliance with the NYSE American $6.0 million stockholders’ equity standard, citing $8.8 revenue from a Boehringer Ingelheim collaboration and expected $14.7 million net proceeds. Trading is expected to resume on NYSE American under PTN on November 12, 2025.
Palatin Technologies, Inc. filed Amendment No. 2 to a Form S-1 for a firm-commitment public offering of 2,307,692 shares of common stock, each sold with a Series J warrant to purchase one share and a Series K warrant to purchase one share. The filing also registers an alternative of up to 2,307,692 pre-funded warrants in lieu of shares, 46,153 underwriter warrants, and the shares underlying all such warrants.
The expected combined offering price range is $6.00–$7.00 (assumed $6.50 midpoint). Underwriting discounts are 7.0%, with a 45‑day over‑allotment option for up to 346,153 additional shares and accompanying warrants. Estimated net proceeds are approximately $13.9 million at the assumed price, intended for working capital and development of MC4R obesity programs. Closing is conditioned on re‑listing the common stock on NYSE American.
Holders unable to exceed ownership caps may elect pre‑funded warrants with a $0.0001 exercise price, subject to 4.99% (or 9.99%) beneficial ownership limits. Shares outstanding were 973,291 as of October 16, 2025.
Palatin Technologies, Inc. reported a net loss of $17.3 million for the year ended June 30, 2025 and management concluded there is substantial doubt about the company’s ability to continue as a going concern. The company sold its Vyleesi product assets and recorded an upfront payment of $9.5 million plus additional consideration, recognizing a $3.13 million gain on the sale and a $2.1179 million gain on eliminated purchase commitments for the fiscal year. Cash and short-term money market deposits included $2,286,603 in money market accounts at June 30, 2025 (compared with $9,089,113 at June 30, 2024). Current liabilities totaled $8,010,030 and certain current assets or balances referenced include $2,564,265. The company continues clinical development across multiple melanocortin receptor (MCR) programs, noting positive topline results reported in 2024–2025 for several programs and projected IND filings for two obesity-focused programs in early 2026. Palatin disclosed extensive financing instruments that may dilute existing shareholders, including convertible preferred stock, options, restricted stock units, and multiple series of warrants outstanding or issuable.